Merve Keskinkilic | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Merve Keskinkilic | Medical Oncology | Best Researcher Award

Medical Oncologist, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital Turkey

Merve Keskinkılıç is a dedicated Medical Oncologist at Burdur State Hospital with a strong academic background in Internal Medicine and Medical Oncology. She earned her M.D. from Dokuz Eylul University Faculty of Medicine and completed her Medical Oncology Fellowship at the same institution. Dr. Keskinkılıç has extensive clinical experience, having served as a Research Fellow at Emory University, USA. Fluent in English (C1 Advanced) and proficient in German (Elementary), she actively participates in international oncology research. Her expertise includes clinical trials, cancer treatment strategies, and translational oncology research, contributing significantly to advancements in the field.

Publication Profile

Scopus

Scholar

🎓 Education

Dr. Keskinkılıç completed her high school education at Balıkesir Science High School (2004-2008) before pursuing medicine at Dokuz Eylul University (2008-2014). She participated in an Oncology Exchange Program at Mansoura University, Egypt (2010). She later obtained an Associate Degree in Healthcare Management from Anadolu University (2014-2017). Her residency in Internal Medicine was completed at Celal Bayar University (2015-2016) and Dokuz Eylul University (2016-2019). She pursued a Medical Oncology Fellowship at Dokuz Eylul University (2019-2024) and is currently undertaking a PhD in Basic Oncology at Dokuz Eylul University Oncology Institute (since 2022). She also worked as a Research Fellow at Emory University, USA (2023).

💼 Experience

Dr. Keskinkılıç began her career as a General Practitioner at Balıkesir Susurluk State Hospital (2014-2015) before becoming a Research Assistant in Internal Medicine at Celal Bayar University (2015-2016) and later at Dokuz Eylul University (2016-2019). She served as a Specialist Doctor at Bitlis Mutki State Hospital (2019) and as a Fellow in Medical Oncology at Dokuz Eylul University (2019-2024). Currently, she is a Medical Oncologist at Burdur Public Hospital (2024-2025) and will join Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital in 2025.

🏆 Awards & Honors

Dr. Keskinkılıç holds several prestigious certifications, including the Turkish Board of Internal Medicine Certificate (2018), Experimental Animal Use Certificate (2019), Oncology Clinical Research Training Certificate (2020), and ESMO Board of Examination Certificate (2023). She has also completed Good Clinical Practices (ICU) and Clinical Research Training and has received certifications in Research Ethics and Clinical Trials. Her contributions to oncology research and education have been recognized through multiple national and international accolades.

🔬 Research Focus

Dr. Keskinkılıç specializes in clinical oncology research, focusing on urothelial, bladder, gastric, prostate, and lung cancers. She is actively involved in multiple clinical trials, serving as a Sub-Investigator in research projects such as THOR (Urothelial Cancer), Niagara (Bladder Cancer), MK3475-859 (Gastric Cancer), Regeneron (Non-Small Cell Lung Cancer), and Radiant 20510 (Prostate Cancer). Her work emphasizes innovative treatment strategies, immunotherapy, and targeted cancer therapies, contributing to the development of advanced oncological treatments. Her internal medicine dissertation evaluated CMV DNA Antigenemia in Allogeneic Bone Marrow Transplant Patients.

Publication Top Notes

  • Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
    • Authors: C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al.
    • Journal: BMC Cancer, 2023
    • Citations: 20

 

  • Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    • Authors: S. Kahraman, E. Erul, M. Seyyar, O. Gumusay, et al.
    • Journal: Future Oncology, 2023
    • Citations: 13

 

  • Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
    • Authors: H. Ç. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen, et al.
    • Journal: The Breast, 2022
    • Citations: 13

 

  • The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor-positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and…
    • Authors: E. C. Yildirim, E. Atag, E. Coban, et al.
    • Journal: The Breast, 2023
    • Citations: 12

 

  • Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia
    • Authors: H. C. Yildirim, C. Kapar, B. Koksal, et al.
    • Journal: Journal of Chemotherapy, 2024
    • Citations: 4

 

  • The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
    • Authors: M. Keskinkilic, H. S. Semiz, G. Polat, et al.
    • Journal: Future Oncology, 2023
    • Citations: 4

 

  • Antibody-Drug Conjugates in Triple Negative Breast Cancer
    • Authors: M. Keskinkilic, R. Sacks
    • Journal: Clinical Breast Cancer, 2024
    • Citations: 3

 

  • 194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience
    • Authors: M. Keskinkılıç, H. S. Semiz, T. Yavuzsen, A. Karaoglu
    • Journal: Annals of Oncology, 2022
    • Citations: 3

 

  • The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma
    • Authors: H. I. Ellez, M. Keskinkilic, et al.
    • Journal: Journal of Clinical Medicine, 2023
    • Citations: 11

 

  • The role of immune checkpoint inhibition in triple-negative breast cancer
    • Authors: K. Tarekegn, M. Keskinkilic, T. J. Kristoff, S. T. Evans, K. Kalinsky
    • Journal: Expert Review of Anticancer Therapy, 2023
    • Citations: 10

 

  • The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer
    • Authors: M. Hizal, B. Bilgin, N. Paksoy, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2023
    • Citations: 5

 

  • CD47 (‘don’t eat me’ signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma
    • Authors: H. S. Semiz, Ü. Küçük, E. Kısa, M. Keskinkılıç, et al.
    • Journal: The Prostate, 2022
    • Citations: 5

 

  • A severe case of levothyroxine intoxication successfully treated in intensive care unit
    • Authors: Y. Savran, T. Mengi, M. Keskinkilic
    • Journal: Journal of Acute Disease, 2018
    • Citations: 11

 

 

Angelika Długosz-Pokorska | cancer research | Women Researcher Award

Posted on by ScienceFather

 Dr. Angelika Długosz-Pokorska | cancer research |Women Researcher Award

 Dr at Medical University of Łódź,  Poland

A dedicated researcher and project leader at the Medical University of Lodz, Poland, with expertise in pharmacological characterization and anticancer drug development. As Principal Investigator and Co-investigator, led projects funded by prestigious grants like OPUS and SONATA, focusing on opioid peptide analogs and alpha-methylidene-delta-lactones. Supervising international student exchanges and engaging in expert activities, workshops, and editorial work. Recognized with numerous awards for scientific excellence, including Rector’s Awards and IF=8.638 for publication series on opioid mimetics and glutathione peroxidase. Committed to advancing medical science through innovative research and academic leadership.

Profile

  1. Scopus

 

  1. Orcid

📜 Employment History:

Research Associate (2017-present) Medical University of Lodz, Poland; Faculty of Medicine. Co-investigator (2016-2021)
Project: Rational design and pharmacological characterization of chimeric cyclic opioid peptide analogs targeting multiple receptors
Grant: OPUS 9, project ID 2015/17/B/ST5/00153. Principal Investigator (2016-2021) Project: Analysis of the anticancer activity of new synthetic alpha-methylidene-delta-lactones in selected cell lines Grant: SONATA, project ID 2015/17/D/NZ3/02226. Supervisor, Project Manager, and Principal Investigator (2018-present) Project: Analysis of the anticancer activity and molecular mechanism of action of new hybrid molecules containing uracil skeleton with an exo-cyclic methylene group Grant: PRELUDIUM13, project ID UMO-2017/25/N/NZ3/01039

📚 Short Research Training:

University of Rouen, France (2014) Laboratoire de Neuropsychopharmacologie Expérimentale

🌍 Activities:

  • Expert Activity/Reviewer (2024)
    Platform: Qeios
  • International Student Exchanges and ERASMUS Supervision (2024)
    Engaging in initiatives and participating in European Union programs, overseeing ERASMUS students.
  • Participation in Scientific Workshops and Research Teams (2024)
    Engaging in workshops aimed at exchanging experiences, self-improvement, and organization.
  • Editorial Work (2023-present)
    Journal: Reviewer for Breast Cancer-Tokyo, ISSN 1340-6868, eISSN 1880-4233.

🏆 Awards and Distinctions:

2022: First-level Special Award for Outstanding Didactic Work by Academic Teachers Medical University of Lodz.

2020: Team Distinction from the Faculty of Chemistry Nicolaus Copernicus University in Toruń Rector’s Award Medical University of Lodz Second-degree scientific award for a series of publications titled: ‘Investigation of the Anticancer Properties of Synthetic Analogues of Compounds Isolated from Plants’. (Impact Factor – 8.034). Polish Intelligent Development Award – Nomination.

2019: Investigation of Anticancer Activity of Synthetic Analogues of Methylenolactones”, IF=4.026PTBioch Bursary Scholarship 44th FEBS Congress “From Molecules to Living Systems”. Rector’s Award Medical University of Lodz Second Prize for Publication: ‘Synthetic Analogues of Coumarin as Novel Agents with Anticancer Activity’. (Impact Factor = 4.173). Rector’s Award Medical University of Lodz Team Second award for Publication Series:

2017: Rector’s Award Medical University of Lodz First Prize for Publication Series: “Synthesis and Investigation of Biological Activity of Opioid Mimetics and Glutathione Peroxidase”. (IF=8.638). Rector’s Award Medical University of Lodz Team First Prize for Publication Series: “Anticancer Properties of Novel Synthetic Dicoumarins”. (IF=6.221) “Investigation of Anticancer Activity of Sesquiterpene Lactones”. (IF=4.994)

2016: Rector’s Award Medical University of Lodz First Prize for Publication Series: “Anticancer Properties of Novel Synthetic Lactones in Combination with Known Anticancer Drugs”. (IF = 8.835)

Publications Top Notes 📝

  • Title: Synthesis of New Chiral β-Carbonyl Selenides with Antioxidant and Anticancer Activity Evaluation-Part I
    • Authors: Laskowska, A., Pacuła-Miszewska, A.J., Obieziurska-Fabisiak, M., et al.
    • Journal: Materials
    • Year: 2024
    • Volume: 17
    • Pages: 1–15
    • Summary: This study focuses on the synthesis of new chiral β-carbonyl selenides and evaluates their antioxidant and anticancer activities, providing valuable insights into potential therapeutic agents.

 

  • Title: New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF7 Cancer Cells
    • Authors: Długosz-Pokorska, A., Perlikowska, R., Janecki, T., et al.
    • Journal: Biologics: Targets and Therapy
    • Year: 2023
    • Volume: 17
    • Pages: 69–83
    • Summary: This article presents a novel uracil analog with potential to reverse resistance to Taxol in MCF7 cancer cells, indicating its promising role as an anticancer agent.

 

  • Title: New Uracil Analog- U-359 can Reverse Resistance to Taxol in MCF-7 cancer cells
    • Authors: Długosz-Pokorska, A., Perlikowska, R., Janecki, T., et al.
    • Journal: Acta Biochimica Polonica
    • Year: 2023
    • Volume: 70
    • Pages: 56
    • Summary: This study explores another uracil analog’s potential to reverse resistance to Taxol in MCF-7 cancer cells, indicating a promising avenue for further research.

 

  • Title: The Influence of Long Carbon Chains on the Antioxidant and Anticancer Properties of N-Substituted Benzisoselenazolones and Corresponding Diselenides
    • Authors: Pacuła-Miszewska, A.J., Obieziurska-Fabisiak, M., Jastrzębska, A., et al.
    • Journal: Pharmaceuticals
    • Year: 2023
    • Volume: 16
    • Pages: 1–11
    • Summary: This research investigates the impact of long carbon chains on the antioxidant and anticancer properties of N-substituted benzisoselenazolones and corresponding diselenides, providing valuable insights into structure-activity relationships.

 

  • Title: Attachment of Chiral Functional Groups to Modify the Activity of New GPx Mimetics
    • Authors: Laskowska, A., Pacuła-Miszewska, A., Długosz-Pokorska, A., et al.
    • Journal: Materials
    • Year: 2022
    • Volume: 16
    • Pages: 1–14
    • Summary: This study explores the modification of GPx mimetics’ activity through the attachment of chiral functional groups, offering potential strategies for enhancing therapeutic effects.